Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
In limited data it's generally reported as well-tolerated, but human safety data is still limited and long-term effects aren't fully characterized
This review applies a contemporary lens (20202025) reflecting methodological and clinical inflection pointswidespread continuous glucose monitoring (CGM), standardized assays for TRL, multi-omics workflows, and the clinical introduction of glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) co-agonistswhile selectively incorporating pre-2020 foundational contributions limited to seminal meta-analyses, consensus statements, pivotal randomized trials, or first-in-field mechanistic studies
Christiansen, R., Bremer, J
10.1038/npp.2015.57 100
US$ 29.93
US$ 21.34
US$ 26.22
US$ 23.49
US$ 25.55
US$ 23.77
US$ 25.11
US$ 24.22
US$ 26.99
